Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

HIV drug comparison study seeks clues to shrink hidden virus

NCT ID NCT05584397

Knowledge-focused Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 40 people with HIV to see if a common drug, tenofovir, causes more immune system activation and helps the virus hide better in the body. Participants are already on stable HIV treatment and will provide blood and gut samples. The goal is to find ways to reduce the hidden HIV reservoir and improve long-term health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People living with HIV (PWH) on stable use of antiretroviral therapy (ART). They will be between 18 and 65 years of age. Children less than 18 years of age are excluded. Women of childbearing potential should not be pregnant to participate.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Confirmed HIV infection, by two different positive antibody tests and/or detectable plasma HIV RNA on two different dates 2. ≥18 and ≤65 years of age 3. Stable use of ART medication for ≥ 1 year 4. No switch of ART regimen within the past 180 days 5. CD4 \> 350/mm3 within the past 180 days 6. HIV RNA \<40 copies / mL on ≥ 2 occasions during continuous ART of ≥ 1 years, with no blip of \>1000 HIV RNA copies / mL 7. Karnofsky score ≥80 8. Willingness and ability to provide informed consent for study participation 9. Willingness to undergo all required study procedures Exclusion Criteria: 1. Active malignancy including myelodysplastic syndrome, or myeloproliferative disease within 24 weeks prior to study entry 2. Prior organ or bone marrow transplantation 3. Diagnosed autoimmune disease 4. Medical need for ongoing treatment with an immunosuppressive drug 5. Diagnosis of AIDS (defined as any AIDS-defining opportunistic infection or cancer, or a history of blood CD4+ T cell count \< 200/μL) 6. Active opportunistic infection 7. Vomiting or diarrhea which prohibits consistent use of ART 8. Pregnant or breastfeeding 9. Excessive ingestion of ethanol determined by an AUDIT score of \>8 10. Substance abuse 11. History of medical non-compliance 12. The following laboratory values (\< 30 days before enrollment): * Hemoglobin \< 8.5 mg/dL * Platelet count \< 100,000/μL * Coagulation (PT/PTT) tests above the normal reference * Creatinine clearance \< 60 mL/min 13. Using disallowed medications: * Systemic corticosteroids * Other immunosuppressive medications (e.g., cyclosporine, sirolimus, tacrolimus, pimecrolimus, tofacitinib) 14. BMI \> 40 15. Pulmonary dysfunction. 16. Use of narcotics.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

HIV infectious disease Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV HIV disease progression HIV-1-infection Inflammation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Washington Positive Research and the Gastroenterology Clinic at Harborview Medical Center

    Seattle, Washington, 98104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.